SCHEMBL4674294

SCHEMBL4674294

O=C(O)C(O)=CC(=O)c1occc1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 2/20 0.39
CYP3A4 P08684 1/20 0.39
POLB P06746 2/20 0.38
KMT2A Q03164 4/20 0.37
MAPT P10636 2/20 0.37
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 1/20 0.36
AKR1C1 Q04828 1/20 0.36
MEN1 O00255 2/20 0.36
KDM4E B2RXH2 1/20 0.36
ACLY P53396 1/20 0.35
CNR1 P21554 1/20 0.33
LMNA P02545 1/20 0.33
HPGD P15428 1/20 0.32
KIF18A Q8NI77 1/20 0.32
MAOB P27338 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674289 1.00 ALDH1A1 (0.39) ALDH1A1MAPK1CYP3A4POLBKMT2A
SCHEMBL4672052 0.88 NPSR1 (0.37) ALDH1A1POLBKMT2AMAPTKDM4E
SCHEMBL4673417 0.88 NPSR1 (0.37) ALDH1A1POLBKMT2AMAPTKDM4E
SCHEMBL4678323 0.87 MMP1 (0.38) MAPTAKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4678326 0.87 MMP1 (0.38) MAPTAKR1C3AKR1C2AKR1C1KDM4E
SCHEMBL4677921 0.79 ALDH1A1 (0.39) ALDH1A1MAPK1CYP3A4POLBKMT2A
SCHEMBL4677919 0.79 ALDH1A1 (0.39) ALDH1A1MAPK1CYP3A4POLBKMT2A
SCHEMBL4672361 0.77 ALDH1A1 (0.34) ALDH1A1MAPK1CYP3A4POLBKMT2A
SCHEMBL4674107 0.76 ALDH1A1 (0.39) ALDH1A1MAPK1CYP3A4POLBKMT2A
SCHEMBL4674114 0.76 ALDH1A1 (0.39) ALDH1A1MAPK1CYP3A4POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885MAPK1 2560/4885CYP3A4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.